Peripheral Treg from PSC and PBC patients also showed no change in their CXCR3 expression with sustained culture in VLDP (Fig. 4b,d), thus VLDP therapy may be applicable for all three autoimmune liver diseases without impairing the recruitment capacity of Treg. The gene discussed is CXCR3; the disease is primary biliary cholangitis.